Novartis’ Jonathan Peacock moves to Amgen
pharmafile | July 23, 2010 | Appointment | Sales and Marketing |Â Â Amgen, appointment, sales and marketingÂ
Amgen has appointed Jonathan Peacock executive VP and chief financial officer with effect from 1 September.
He will move to the company from Novartis, where he has served as chief financial officer and administration officer since 2005.
Prior to that Jonathan was a partner at McKinsey and Company, where he was co-leader of the European corporate finance practice, and he has also been a partner at Price Waterhouse.
At Amgen he takes over from Michael Kelly, who has been serving as acting chief financial officer since May 2010.
In his new role Jonathan will be responsible for Amgen’s finance and investor relations operations, reporting chairman and chief executive Kevin Sharer.
“I am delighted to have a leader of Jonathan’s talent, vision and international experience join Amgen at a time when we are expanding globally,” Sharer said.
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer
Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) …

Amgen opens new biomanufacturing facility in Ohio, US
Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …






